← Back to Analyst Consensus 
ELAN Buy
Elanco Animal Health Inc
Current Price —
Implied Upside —
Analysts 22
30-Day Momentum
▲ 1 upgrades / ▼ 1 downgrades / 0 reiterations from 2 firms
Next Earnings
Nov 6, 2026 (11 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 20, 2026 | Jefferies | downgrade | Buy → Hold | — | 52% |
| Oct 16, 2026 | Goldman Sachs | initiate | — → Buy | — | 54% |
| Aug 6, 2026 | UBS | maintain | Buy → Buy | — | 54% |
| Aug 6, 2026 | Keybanc | maintain | Overweight → Overweight | — | 53% |
| Jul 22, 2026 | Morgan Stanley | maintain | Equal-Weight → Equal-Weight | — | 54% |
| Jun 18, 2026 | TD Cowen | maintain | Buy → Buy | — | 54% |
| May 7, 2026 | Citigroup | maintain | Buy → Buy | — | 54% |
| May 7, 2026 | JP Morgan | maintain | Overweight → Overweight | — | 54% |
| Apr 15, 2026 | Citigroup | initiate | — → Buy | — | 54% |
| Feb 25, 2026 | Morgan Stanley | maintain | Equal-Weight → Equal-Weight | $24 | 54% |
| Feb 25, 2026 | Keybanc | maintain | Overweight → Overweight | $29 | 53% |
| Feb 24, 2026 | Leerink Partners | maintain | Outperform → Outperform | $30 | 50% |
| Feb 19, 2026 | JP Morgan | maintain | Overweight → Overweight | $28 | 54% |
| Jan 22, 2026 | Piper Sandler | upgrade | Neutral → Overweight | $30 | 54% |
| Dec 18, 2025 | Morgan Stanley | maintain | Equal-Weight → Equal-Weight | $22 | 54% |
| Dec 9, 2025 | Barclays | initiate | — → Overweight | $30 | 53% |
| Nov 21, 2025 | Keybanc | initiate | — → Overweight | $27 | 53% |
| Nov 6, 2025 | UBS | maintain | Buy → Buy | $27 | 54% |
| Oct 20, 2025 | UBS | maintain | Buy → Buy | $25 | 54% |
| Oct 7, 2025 | JP Morgan | upgrade | Neutral → Overweight | $24 | 54% |
| Sep 24, 2025 | Stifel | maintain | Buy → Buy | $23 | 53% |
| Aug 11, 2025 | Piper Sandler | maintain | Neutral → Neutral | $18 | 54% |
| Aug 8, 2025 | UBS | maintain | Buy → Buy | $19 | 54% |
| Jul 23, 2025 | UBS | maintain | Buy → Buy | $18 | 54% |
| Jul 17, 2025 | Leerink Partners | upgrade | Market Perform → Outperform | $18 | 50% |
| Jul 2, 2025 | Stifel | maintain | Buy → Buy | $17 | 53% |
| Jun 26, 2025 | William Blair | upgrade | Market Perform → Outperform | $0 | 48% |
| May 19, 2025 | Stifel | maintain | Buy → Buy | $16 | 53% |
| May 8, 2025 | Stifel | maintain | Buy → Buy | $15 | 53% |
| Apr 14, 2025 | Stifel | maintain | Buy → Buy | $13 | 53% |
| Mar 6, 2025 | Piper Sandler | maintain | Neutral → Neutral | $12 | 54% |
| Feb 26, 2025 | UBS | maintain | Buy → Buy | $17 | 54% |
| Feb 26, 2025 | Morgan Stanley | maintain | Equal-Weight → Equal-Weight | $13 | 54% |
| Feb 26, 2025 | Stifel | maintain | Buy → Buy | $15 | 53% |
| Feb 26, 2025 | Barclays | maintain | Overweight → Overweight | $19 | 53% |
| Feb 21, 2025 | Stifel | maintain | Buy → Buy | $16 | 53% |
| Jan 29, 2025 | Morgan Stanley | maintain | Equal-Weight → Equal-Weight | $14 | 54% |
| Jan 7, 2025 | Stifel | maintain | Buy → Buy | $18 | 53% |
| Dec 9, 2024 | UBS | initiate | — → Buy | $18 | 54% |
| Dec 2, 2024 | Leerink Partners | initiate | — → Market Perform | $14 | 50% |
| Nov 8, 2024 | Barclays | maintain | Overweight → Overweight | $20 | 53% |
| Oct 28, 2024 | Barclays | maintain | Overweight → Overweight | $19 | 53% |
| Sep 23, 2024 | Barclays | maintain | Overweight → Overweight | $22 | 53% |
| Sep 19, 2024 | Stifel | reiterate | Buy → Buy | $20 | 53% |
| Sep 19, 2024 | Morgan Stanley | downgrade | Overweight → Equal-Weight | $15 | 54% |
| Jul 1, 2024 | Piper Sandler | maintain | Neutral → Neutral | $16 | 54% |
| Jun 28, 2024 | Barclays | maintain | Overweight → Overweight | $21 | 53% |
| May 13, 2024 | Piper Sandler | reiterate | Neutral → Neutral | $19 | 54% |
| May 9, 2024 | Barclays | maintain | Overweight → Overweight | $23 | 53% |
| Mar 12, 2024 | Piper Sandler | reiterate | Neutral → Neutral | $18 | 54% |
Price Target Trend
Jun 16, 2026 Latest: $30.31 Oct 24, 2026
EPS Estimates
+1q $0.19
Lo: $0.17 Hi: $0.23
11 analysts ▲1
0q $0.21
Lo: $0.19 Hi: $0.24
12 analysts ▲2
+1y $1.29
Lo: $1.22 Hi: $1.44
14 analysts ▲1
0y $1.14
Lo: $1.10 Hi: $1.22
14 analysts ▲1
Cross-Platform Signals
No cross-platform signals in the last 90 days